Actavis Net Revenue Increases 59% to $2.779 Billion in Fourth Quarter 2013LEARN MORE>
Actavis Completes Forest Laboratories Acquisition
>Go!

News

Webcast
Actavis plc at Bernstein's Thirty-First Annual Strategic Decisions Conference (Replay)
05/28/15 at 11:00 a.m. ET
Webcast
Actavis plc at UBS Global Healthcare Conference 2015 (Replay)
05/18/15 at 10:30 a.m. ET
Keyword Search
05.27.2015
Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults
05.27.2015
Infectious Disease Experts, Scientists and Clinicians Join Forces on SHARE ID™ to Accelerate the Battle Against Antibiotic-resistant Infections
05.22.2015
Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR
05.20.2015
Actavis to Present at Bernstein's Thirty-First Annual Strategic Decisions Conference 2015
05.18.2015
Actavis Launches NAMZARIC™ (memantine hydrochloride extended-release and donepezil hydrochloride), a Fixed-Dose Combination Therapy for the Treatment of Moderate to Severe Alzheimer's Disease
<>
ELECTRONIC ENROLLMENT